Renin angiotensin aldosterone system (RAAS) inhibitors in the prevention of early renal disease in diabetes

F1000 Medicine Reports

Volumn 2, Issue 1, 2010, Pages

  Gnudi, Luigi ^a   Goldsmith, David ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GLICLAZIDE; HYPOCHOLESTEROLEMIC AGENT; INDAPAMIDE PLUS PERINDOPRIL; LISINOPRIL; LOSARTAN; OLMESARTAN; RAMIPRIL; TRANDOLAPRIL; VERAPAMIL;

ALBUMINURIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINOPATHY; REVIEW;

EID: 77955058990     PISSN: None     EISSN: 17575931     Source Type: Journal    
DOI: 10.3410/M2-18     Document Type: Review

References (16)

1. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H: Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982, 1:1430-2.
2. Gnudi L, Thomas SM, Viberti G: Mechanical forces in diabetic kidney disease: a trigger for impaired glucose metabolism. J Am Soc Nephrol 2007, 18:2226-32. (Pubitemid 47203836)
3. Karalliedde J, Viberti G: Microalbuminuria and cardiovascular risk. Am J Hypertens 2004, 17:986-93.
4. Ritz E: Nephropathy in type 2 diabetes. J Intern Med 1999, 245:111-26.
5. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler MC, Klein R: Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009, 361:40-51.
6. Chaturvedi N; The EUCLID study group: Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997, 349:1787-92.
7. Bilous R, Chaturvedi N, Sjølie AK, Fuller J, Klein R, Orchard T, Porta M, Parving HH: Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009, 151:11-4.
8. British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association: JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005, 91(Suppl 5):v1-52.
9. Jerums G, Panagiotopoulos S, Premaratne E, Power DA, MacIsaac RJ: Lowering of proteinuria in response to antihypertensive therapy predicts improved renal function in late but not in early diabetic nephropathy: a pooled analysis. Am J Nephrol 2008, 28:614-27. (Pubitemid 351832449)
10. Bilous R: Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? Diabet Med 2008, 25(Suppl 2):25-9.
11. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-89.
12. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR: Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008, 359:1565-76.
13. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators: Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004, 351:1941-51.
14. Patel A; ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370:829-40.
15. Haller HG: Prevention of albuminuria and cardiovascular morbidity with olmesartan: the ROADMAP trial. Paper presented at American Society of Nephrology Renal Week 2009: 27 October - 1 November 2009; San Diego, CA, USA. Abstract 7026.
16. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253-9.